PoC Molecular Diagnostics Market size to exceed USD 2.5bn by 2025

PoC Molecular Diagnostics Market size is to exceed USD 2.5 billion by 2025; according to a new research report by Global Market Insights, Inc.
 

Increasing prevalence of infectious disease such as gonorrhea, syphilis, HIV and Hepatitis C, across the globe will positively impact point of care molecular (POC) diagnostics market growth over the analysis time frame. For instance, every year around millions of people are infected with HIV globally that boosts the demand for PoC molecular diagnostic tests.  Point of care technology provides rapid actionable information pertaining to infectious disease thereby allowing early diagnosis to control its severity. Therefore, growing availability of such advanced biomedical PoC tests enabling early detection of dreadful diseases will boost point of care molecular diagnostics market growth

 

Request Sample Buy NowInquiry Before Buying 

 

Increasing adoption of technologically advanced point of care diagnostic tests will surge the industry growth in forthcoming years. Point of care molecular diagnostics are efficient medical tests that provide real-time patient data. Moreover, PoC molecular tests provide faster access to the test results and help clinicians to determine suitable course of action or treatment for patients in very less time. Additionally, point of care tests are the perfect combination of high performing devices with minimum complexity that fosters its preference. However, complex regulatory scenario for biomedical PoC tests associated with biomedical PoC tests may impede point of care molecular diagnostics market growth to certain extent.
 

PoC Molecular Diagnostics Market

Get more details on this report - Request Free Sample PDF
 

Mass spectrometry segment of point of care molecular diagnostics market is anticipated to witness more than 6.5% CAGR throughout the forecast time frame. Substantial growth is attributed to the ongoing advancements in mass spectrometry techniques. Furthermore, advanced mass spectrometry technique enables rapid measurements of exogenous and endogenous molecules that increases its adoption amongst the healthcare professionals thereby, augmenting the segmental growth.
 

Hepatitis B segment of PoC molecular diagnostics market was valued around USD 110 million in 2018. Considerable revenue size is attributable to increasing prevalence of Hepatitis B Virus infection in Asia Pacific and another developing region. Industry players focus on developing point of care molecular diagnostics test possessing significant accuracy. Several companies have introduced advanced point of care molecular diagnostic tests that includes qualitative immunoassay for accurate and efficient detection of HBsAg in blood accurately. For instance, in 2019, Abbott has developed SD BIOLINE HBSAG 2 Hepatitis tests. These tests are used for detection of hepatitis B that identifies HBsAg in serum or plasma with high degree of sensitivity. Above mentioned factors will stimulate the business growth in forthcoming years.
 

Browse key industry insights spread across 150 pages with 130 market data tables & 12 figures & charts from the report, “PoC Molecular Diagnostics Market Size By Technology [Polymerase Chain Reaction (Real Time PCR, DNA/RNA Purification), In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification,], By Infectious Diseases (MRSA, Clostridium difficile, Vancomycin-resistant Enterococci, Carbapenem-Resistant Bacteria Testing, Flu, Respiratory Syncytial Virus, Candida, Tuberculosis and Drug-resistant TB, Meningitis, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HIV , Hepatitis C, Hepatitis B, HPV, Syphilis),  Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, South Korea, Malaysia, Thailand, Vietnam, Philippines, Australia, Brazil, Argentina, Mexico, South Africa, Nigeria, Egypt, Morocco, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/point-of-care-poc-molecular-diagnostics-market
 

North America PoC molecular diagnostics market held around 40% revenue share in 2018. Growing research and development practices in countries such as the U.S. and Canada will surge demand for point of care molecular diagnostics market. For instance, according to NCBI, several research centers in the U.S. have been keenly studying benefits of PoC tests for detecting threat from infectious agents released during bioterrorism. Moreover, favorable regulatory scenario for PoC molecular diagnostic tests in North America should propel the regional growth.
 

Few industry players operational in PoC molecular diagnostics market are Danaher, Roche, Abbott, Bayer, BioMerieux, Bio-Rad Laboratories and Sysmex. Industry players are implementing strategic initiatives such as collaborations, product launches, geographic expansions, mergers and acquisitions in order to sustain industry competition to acquire prominent market share. For instance, in June 2019, Abbott launched HBA1C first ever rapid point of care test to aid diabetes that will enhance its product portfolio and spur the business growth.
 

Inquiry Before BuyingRequest Sample
 

Point of care molecular diagnostics market. research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:
 

PoC Molecular Diagnostics Market, By Product (USD million)

  • Polymerase chain reaction (PCR)
    • Real Time PCR (RT-PCR)
    • DNA / RNA purification
  • In Situ hybridization
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • Isothermal amplification
  • Others

By Infectious Diseases (USD million)

  • MRSA
  • Clostridium difficile
  • Vancomycin-resistant Enterococci
  • Carbapenem-resistant bacteria testing
  • Flu
  • Respiratory syncytial virus
  • Candida
  • Tuberculosis and drug-resistant TB
  • Meningitis
  • Gastro-intestinal panel testing
  • Chlamydia
  • Gonorrhea
  • HIV
  • Hepatitis C
  • Hepatitis B
  • HPV
  • Syphilis
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Malaysia
    • Thailand
    • Vietnam
    • Philippines
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Nigeria
    • Egypt
    • Morocco
    • Saudi Arabia
    • UAE

 

Chat With Us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info. I Agree